EV Biologics Statistics
Total Valuation
EV Biologics has a market cap or net worth of 826,210.
| Market Cap | 826,210 |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
EV Biologics has 10.23 million shares outstanding.
| Current Share Class | 10.23M |
| Shares Outstanding | 10.23M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.09 |
| PB Ratio | 0.02 |
| P/TBV Ratio | 0.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.11, with a Debt / Equity ratio of 0.15.
| Current Ratio | 3.11 |
| Quick Ratio | 0.80 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0.27 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 0.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 284 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, EV Biologics has paid 27,594 in taxes.
| Income Tax | 27,594 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -66.31% in the last 52 weeks. The beta is 0.95, so EV Biologics's price volatility has been similar to the market average.
| Beta (5Y) | 0.95 |
| 52-Week Price Change | -66.31% |
| 50-Day Moving Average | 0.15 |
| 200-Day Moving Average | 0.73 |
| Relative Strength Index (RSI) | 37.95 |
| Average Volume (20 Days) | 3,134 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, EV Biologics had revenue of 9.47 million and -551,581 in losses. Loss per share was -0.23.
| Revenue | 9.47M |
| Gross Profit | 1.54M |
| Operating Income | 154,858 |
| Pretax Income | -523,987 |
| Net Income | -551,581 |
| EBITDA | n/a |
| EBIT | 154,858 |
| Loss Per Share | -0.23 |
Balance Sheet
The company has 12.40 million in cash and 6.47 million in debt, giving a net cash position of 5.94 million or 0.58 per share.
| Cash & Cash Equivalents | 12.40M |
| Total Debt | 6.47M |
| Net Cash | 5.94M |
| Net Cash Per Share | 0.58 |
| Equity (Book Value) | 42.23M |
| Book Value Per Share | 17.52 |
| Working Capital | 35.33M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 16.24%, with operating and profit margins of 1.63% and -5.82%.
| Gross Margin | 16.24% |
| Operating Margin | 1.63% |
| Pretax Margin | -5.53% |
| Profit Margin | -5.82% |
| EBITDA Margin | n/a |
| EBIT Margin | 1.63% |
| FCF Margin | n/a |
Dividends & Yields
EV Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.69% |
| Shareholder Yield | -0.69% |
| Earnings Yield | -66.76% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 9, 2017. It was a reverse split with a ratio of 0.2.
| Last Split Date | Nov 9, 2017 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
EV Biologics has an Altman Z-Score of 1.58 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.58 |
| Piotroski F-Score | 1 |